PT  - JOURNAL ARTICLE
AU  - A C Antoniou
AU  - P D P Pharoah
AU  - S Narod
AU  - H A Risch
AU  - J E Eyfjord
AU  - J L Hopper
AU  - H Olsson
AU  - O Johannsson
AU  - Å Borg
AU  - B Pasini
AU  - P Radice
AU  - S Manoukian
AU  - D M Eccles
AU  - N Tang
AU  - E Olah
AU  - H Anton-Culver
AU  - E Warner
AU  - J Lubinski
AU  - J Gronwald
AU  - B Gorski
AU  - H Tulinius
AU  - S Thorlacius
AU  - H Eerola
AU  - H Nevanlinna
AU  - K Syrjäkoski
AU  - O-P Kallioniemi
AU  - D Thompson
AU  - C Evans
AU  - J Peto
AU  - F Lalloo
AU  - D G Evans
AU  - D F Easton
TI  - Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies
AID  - 10.1136/jmg.2004.024133
DP  - 2005 Jul 01
TA  - Journal of Medical Genetics
PG  - 602--603
VI  - 42
IP  - 7
4099  - http://jmg.bmj.com/content/42/7/602.short
4100  - http://jmg.bmj.com/content/42/7/602.full
SO  - J Med Genet2005 Jul 01; 42
AB  - A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.